From London to Amsterdam: what the EMA’s move means for medicines regulation

Amsterdam is to become the new home of the European Medicines Agency (EMA) following a vote by EU ministers on November 20, 2017, during which lots were drawn to break a tie between Amsterdam and Milan in the final round.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Takeda sees off UK challenge to Elvanse SPC

28 September 2026 Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.

Pharma

Mylan throws down new gauntlet in Novo Wegovy patent fight

25 September 2026 Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.

Pharma

Novartis defeats Orange Book challenge but suffers EU setback

24 September 2026 An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.

More features

Takeda sees off UK challenge to Elvanse SPC

Mylan throws down new gauntlet in Novo Wegovy patent fight

Novartis defeats Orange Book challenge but suffers EU setback

Behind the case: How Novartis defended its blockbuster Entresto in the UK

Leading European patent litigator to join Carpmaels & Ransford

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Beyond the primary patent: How pharma can build competitive barriers

Patent lawyers and judges discuss lofty UPC issues in grand London venue

From London to Amsterdam: what the EMA’s move means for medicines regulation

More on this story

Editor's picks

Editor's picks

More features